Invivoscribe

Experts in providing molecular products and services for oncology testing


Invivoscribe® is a global leader in hemato-oncology offering a full range of molecular testing products and services. Invivoscribe provides a comprehensive selection of PCR-based products, including B- & T-cell clonality assays (IGH, IGK, TRG, TRB), chromosome translocations, the CDx FLT3 Mutation Assay, NGS gene panels and minimal residual disease (MRD) solutions with bioinformatics software.

Invivoscribe solutions are available as research use only testing reagents and controls as well as CE-marked in vitro diagnostic products.

Improving Lives with Precision Diagnostics®

Bio-Connect Diagnostics supplies all their products in the Benelux. If you have any questions, please contact the helpdesk.

Major product lines from Invivoscribe

  • B-cell and T-cell clonality assays
  • FLT3 assays
  • MRD solutions
  • IVD-products
  • Gene translocations
  • DNA and RNA controls, sensitivity- and proficiency-panelss

Generating clinically actionable results that optimize treatments

Invivoscribe’s assays inform and guide the patient’s physician from diagnosis through the entire course of therapy.

IVDR transition strategy

Popular products

IdentiClone IGK Gene Clonality Assay – ABI Fluorescence Detection (9-102-0021)
IdentiClone IGH Gene Clonality Assay – ABI Fluorescence Detection (9-101-0061)
IdentiClone T Cell Receptor Gamma Gene Rearrangement Assay 2.0 – ABI Detection (9-207-0101)
IdentiClone TCRB Gene Clonality Assay – ABI Fluorescence Detection (9-205-0011)
IdentiClone TCRB + TCRG T-Cell Clonality Assay ABI Fluorescence Detection (9-200-0011)
LymphoTrack Dx IGK Assay Panel – MiSeq (9-122-0019)
LymphoTrack Dx IGH Assay Panel – MiSeq (9-121-0039)
IGH Tube A – 6FAM (2-101-0011)
IGH Tube B – 6FAM (2-101-0101)
IGK Tube A – 6FAM (2-102-0011)
More product can be found in our webshop

Explore recent scientific contributions using Invivoscribe’s products

Key opinion leaders across the world have recently published papers that discuss the advantages of using highly sensitive next-generation sequencing (NGS) for Minimal Residual Disease (MRD) testing.

  • Ha J, Lee H, Shin S, et al. Ig gene clonality analysis using next-generation sequencing for improved minimal residual disease detection with significant prognostic value in multiple myeloma patients. J Mol Diagn. 2022;24(1):48-56.
  • Ho C, Syed M, Roshal M, et al. Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: feasibility, challenges, and direct comparison with high-sensitivity flow cytometry. J Mol Diagn. 2021;23(2):181-199.
  • Kadkol SS, Bland J, Kavanaugh A, Ni H, Nehru V, Peace D. Ngs analysis of clonality and minimal residual disease in a patient with concurrent richter’s transformation and cll/sll. Case Rep Hematol. 2021;2021:9740281.
  • Kim M, Jeon K, Hutt K, et al. Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing. PLoS One. 2021;16(6):e0253541.
  • Ho CC, Tung JK, Zehnder JL, Zhang BM. Validation of a next-generation sequencing-based t-cell receptor gamma gene rearrangement diagnostic assay: transitioning from capillary electrophoresis to next-generation sequencing. J Mol Diagn. 2021;23(7):805-815.
  • Cheng S, Inghirami G, Cheng S, Tam W. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. J Hematol Oncol. 2018;11(1):105.
  • Stamatopoulos B, Timbs A, Bruce D, et al. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia. Leukemia. 2017;31(4):837-845.
  • Levis MJ, Perl AE, Altman JK, et al. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018;2(8):825-831.
  • Arcila ME, Yu W, Syed M, et al. Establishment of immunoglobulin heavy (Igh) chain clonality testing by next-generation sequencing for routine characterization of b-cell and plasma cell neoplasms. J Mol Diagn. 2019;21(2):330-342.
  • Yao Q, Bai Y, Orfao A, Chim CS. Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. Front Oncol. 2019;9:449.

Related news

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.

Need help? Contact our technical support
Contact